Antineoplastic agent, Tyrosine kinase inhibitor Medicines in UAE
144 medicines available
About Antineoplastic agent, Tyrosine kinase inhibitor Medicines
This page lists all Antineoplastic agent, Tyrosine kinase inhibitor medicines available in UAE pharmacies.
Click on any medicine name to view detailed information including uses, dosage, side effects, and availability.
Complete List of Antineoplastic agent, Tyrosine kinase inhibitor Medicines
Class: | Tyrosine kinase inhibitor (TKI)
Use: | Treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, particularly for patients with T790M mutation after progression on prior EGFR TKI...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, particularly in patients with T790M mutation who have progressed on prior EGFR-targeted...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS)
Adult dose: | 800 mg orally once daily, taken without food; may be reduced ...
Class: | Bruton's tyrosine kinase (BTK) inhibitor
Use: | Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy
Adult dose:...
Class: | Bruton tyrosine kinase (BTK) inhibitor
Use: | Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy
Adult dose: |...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistan...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adults with non-small cell lung cancer (NSCLC) that is RET fusion-positive, and for adults and pediatric patients 12 years and older with advan...
Class: | Tyrosine Kinase Inhibitor
Use: | Treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), and other RET-altered...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced or metastatic medullary thyroid cancer (MTC), and advan...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced or metastatic medullary thyroid cancer (MTC), and advan...
Class:| Tyrosine kinase inhibitor
Use:| Treatment of advanced renal cell carcinoma, gastrointestinal stromal tumors after disease progression on or intolerance to imatinib, and pancreatic neuroendoc...
Class:| Tyrosine kinase inhibitor
Use:| Treatment of advanced renal cell carcinoma, gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate, and pancreatic ne...
Class:| Tyrosine kinase inhibitor
Use:| Treatment of advanced renal cell carcinoma, gastrointestinal stromal tumor after disease progression on or intolerance to imatinib, and pancreatic neuroendocr...
Class: | Tyrosine kinase inhibitor
Use: | Sunitinib Malate (SUTENT) is used for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate...
Class: | Tyrosine kinase inhibitor
Use: | Sunitinib Malate (SUTENT) is used for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylat...
Class:| Tyrosine kinase inhibitor
Use:| Treatment of advanced renal cell carcinoma, gastrointestinal stromal tumor after disease progression on or intolerance to imatinib, and pancreatic neuroendocr...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, particularly in those who have received at least one prior anti...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, especially in those who have received at least one prior anti-H...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, in combination with trastuzumab and capecitabine, who have rece...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, particularly in those who have received at least one prior anti...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, including those who have received one or more prior anti-HER2 t...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive metastatic breast cancer, including those with brain metastases, who have received at least one prior anti-HE...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, in combination with trastuzumab and capecitabine, who have rece...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, particularly in those who have received at least one prior anti...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, in combination with other therapies
Adult dose: | 300 mg oral...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer, in combination with capecitabine, particularly in ...
Class: | Bruton's tyrosine kinase (BTK) inhibitor
Use: | Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy; treatment of adult patients with ch...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adults with previously treated, advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
Adult dose: | 13.5 mg o...